-
2008
27 November 2008: Announcement no. 3, 2008: Zealand Pharma and Helsinn Healthcare S...
-
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 1 compound in phase II, 2 c...
GAP-134/ZP1609 Publications
Laurent, G., Leong-Poi,H., Moe, G., Hu, X., So, P.-S.S., Ramadeen, A., Doumanovskaia, L., and Konig, A.:
Effects of Oral Gap Junction Conduction-Enhancing Antiarrhythmic Peptide GAP-134 on Experimental Atrial Fibrillation in Dogs
Abstract from The American Heart Association Meeting and Scientific Sessions 2007, Orlando, Florida, USA, Nov. 3-7, 2007.
Rossman, E.I., Liu, K., Morgan, G.A., Swillo, R.E., Butera, J., Gruver, M., Kantrowitz, J., Haugan, K., Petersen, J.S. and Hennan, J.K.:
Effects of the Gap Junction Modifier, GAP-134, on Conduction and Atrial Fibrillation/Flutter Inducibility in Dogs
Abstract from The American Heart Association Meeting and Scientific Sessions 2007, Orlando, Florida, USA, Nov. 3-7, 2007.
Butera, J.A., Larsen, B.D., Kerns, K., Di, L., Hennan, J.K., Swillo, R., Morgan, G., Huselton, C., Unwalla, R. and Petersen, J.S.:
The Discovery of Potent Gap-junction Modifiers as Novel Antiarrhythmic Agents - From Stable Hexa-peptides to Orally Available Small Molecules.
Abstract for American Chemistry Society Fall Meeting 2007, August 19-23, 2007, Boston, MA, USA
Hennan, J.K., Liu, K., Morgan, G., Swillo, R., Butera, J., Kantrowitz, J., Haugan, K., Larsen, B.D., and Petersen, J.S.:
Pharmacological characterization of GAP-134, an orally bioavailable small molecule gap junction modifier, in mouse, rat and canine arrhythmia models
Abstract p 95, International Gap Junction Conference, Elsinore, Denmark, 4-7 August 2007
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.